Mitochondria Targeting of Oxidative Phosphorylation Inhibitors to Alleviate Hypoxia and Enhance Anticancer Treatment Efficacy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Hypoxia in tumors hinders cancer therapy. Inhibiting oxidative phosphorylation (OXPHOS) shows promise, but current drugs cause toxicity. New strategies focus on targeted OXPHOS inhibitors to improve efficacy and reduce side effects.
Area Of Science
- Oncology
- Cancer Metabolism
- Mitochondrial Biology
Background
- Tumor hypoxia is linked to poor treatment outcomes and immune suppression.
- Hypoxia drives cancer cells to glycolysis, acidifying the tumor microenvironment (TME) and impairing immune responses.
- Pharmacological inhibition of oxidative phosphorylation (OXPHOS) is a strategy to combat hypoxia and sensitize tumors.
Purpose Of The Study
- To review limitations of clinically tested OXPHOS inhibitors (OXPHOSi).
- To explore the potential of mitochondria-targeted OXPHOSi for improved efficacy and reduced toxicity.
- To discuss the role of reactive oxygen species (ROS) and triphenylphosphonium (TPP) in OXPHOS inhibition.
Main Methods
- Review of existing literature on OXPHOS inhibitors, including metformin, atovaquone, tamoxifen, BAY 87-2243, and IACS-010759.
- Analysis of strategies to enhance therapeutic windows, such as mitochondria-targeting.
- Discussion of the impact of OXPHOS inhibition on ROS production and mitochondrial function.
Main Results
- Clinically tested OXPHOSi face challenges with moderate efficacy and significant toxicity due to off-target effects.
- Mitochondria-targeted OXPHOSi, like TPP conjugates, show potential for increased tumor uptake and reduced systemic toxicity.
- OXPHOS inhibition can induce ROS, influencing the efficacy of concurrent therapies like chemotherapy and radiotherapy.
Conclusions
- There is a need for novel OXPHOS inhibition strategies to overcome limitations of current therapies.
- Mitochondria-targeted OXPHOSi represent a promising approach to enhance anticancer efficacy while minimizing side effects.
- Understanding the interplay between OXPHOS inhibition, ROS production, and TME is crucial for optimizing cancer treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...